|
Jul 24
|
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
|
|
Jul 24
|
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
|
|
Jul 24
|
Johnson & Johnson showcases latest advancements in Alzheimer's research at AAIC 2025
|
|
Jul 24
|
Low IV Alert: Stocks that Could be Ready to Pop
|
|
Jul 24
|
Diffuse Large B-cell Lymphoma Market Research Report 2025-2035 | Personalized Medicine and Precision Treatment Trends in DLBCL
|
|
Jul 24
|
Janssen’s Darzalex new indication gains EC approval for SMM
|
|
Jul 24
|
Looking Beyond Yield for the Safest Dividend Payers
|
|
Jul 24
|
Mountain Valley MD Holdings Announces Changes to Board of Directors
|
|
Jul 23
|
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
|
|
Jul 23
|
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
|
|
Jul 23
|
Jim Cramer on Johnson & Johnson: “J&J is Just Beginning Its Move”
|
|
Jul 23
|
Shopify and Unity downgraded: Wall Street's top analyst calls
|
|
Jul 23
|
European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma
|
|
Jul 23
|
European Commission approves IMBRUVICA® (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant
|
|
Jul 23
|
Cancer Pain 8 Major Market Forecast Report 2025-2034 | Opioids and Non-Opioids Drive Innovations, Medical Cannabis Emerges as Alternative
|
|
Jul 23
|
Ipsen announces changes to its Executive Committee
|
|
Jul 22
|
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
|
|
Jul 22
|
AZN Commits USD50B to US Manufacturing Expansion Amid Tariff Pressures
|
|
Jul 22
|
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
|
|
Jul 22
|
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
|